Characterization of intrathecal vasopressin-induced antinociception, scratching behavior, and motor suppression

Cindy L. Thurston, Ian G. Campbell, E. S. Culhane, Earl Carstens, L. R. Watkins

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Intrathecal (IT) administration of vasopressin produces antinociception, scratching behavior, and motor suppression. The present experiments characterized these effects with regards to the following: 1) VP receptor specificity, 2) possible involvement of endogenous opiates, 3) possible involvement of seizure activity, and 4) whether the antinociception is due to direct actions of VP at the spinal cord. These studies showed that IT administration of a V1-specific vasopressin antagonist completely blocked the antinociception, scratching behavior, and motor suppression produced by 25 ng IT vasopressin. Furthermore, IT administration of the vasopressin metabolite, [pGlu4,Cyt6]AVP(4-9), produced none of the effects produced by vasopressin. Systemic administration of the opiate antagonists naloxone (1 mg/kg IP) and naltrexone (10 mg/kg IP) had no significant effect on the antinociception produced by IT vasopressin, whereas naltrexone potentiated the scratching behavior. Neither the IT vasopressin-induced antinociception nor scratching behavior was affected by pretreatment with the anticonvulsant sodium valproate. In addition, IT vasopressin inhibited the tail flick reflex in rats with transected spinal cords, demonstrating direct spinal effects of vasopressin. In conclusion, IT administration of vasopressin produces antinociception, scratching behavior, and motor suppression via activation of VP-specific receptors in the spinal cord.

Original languageEnglish (US)
Pages (from-to)17-25
Number of pages9
JournalPeptides
Volume13
Issue number1
DOIs
StatePublished - 1992

Fingerprint

Vasopressins
Spinal Cord
Naltrexone
Opiate Alkaloids
Viral Structural Proteins
Opioid Peptides
Valproic Acid
Naloxone
Metabolites
Anticonvulsants
Reflex
Tail
Rats
Seizures
Chemical activation

Keywords

  • Analgesia
  • Opiates
  • Pain
  • Spinal cord
  • Vasopressin

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Characterization of intrathecal vasopressin-induced antinociception, scratching behavior, and motor suppression. / Thurston, Cindy L.; Campbell, Ian G.; Culhane, E. S.; Carstens, Earl; Watkins, L. R.

In: Peptides, Vol. 13, No. 1, 1992, p. 17-25.

Research output: Contribution to journalArticle

Thurston, Cindy L. ; Campbell, Ian G. ; Culhane, E. S. ; Carstens, Earl ; Watkins, L. R. / Characterization of intrathecal vasopressin-induced antinociception, scratching behavior, and motor suppression. In: Peptides. 1992 ; Vol. 13, No. 1. pp. 17-25.
@article{2c3116beb2854b9582cb3c8807d4ff55,
title = "Characterization of intrathecal vasopressin-induced antinociception, scratching behavior, and motor suppression",
abstract = "Intrathecal (IT) administration of vasopressin produces antinociception, scratching behavior, and motor suppression. The present experiments characterized these effects with regards to the following: 1) VP receptor specificity, 2) possible involvement of endogenous opiates, 3) possible involvement of seizure activity, and 4) whether the antinociception is due to direct actions of VP at the spinal cord. These studies showed that IT administration of a V1-specific vasopressin antagonist completely blocked the antinociception, scratching behavior, and motor suppression produced by 25 ng IT vasopressin. Furthermore, IT administration of the vasopressin metabolite, [pGlu4,Cyt6]AVP(4-9), produced none of the effects produced by vasopressin. Systemic administration of the opiate antagonists naloxone (1 mg/kg IP) and naltrexone (10 mg/kg IP) had no significant effect on the antinociception produced by IT vasopressin, whereas naltrexone potentiated the scratching behavior. Neither the IT vasopressin-induced antinociception nor scratching behavior was affected by pretreatment with the anticonvulsant sodium valproate. In addition, IT vasopressin inhibited the tail flick reflex in rats with transected spinal cords, demonstrating direct spinal effects of vasopressin. In conclusion, IT administration of vasopressin produces antinociception, scratching behavior, and motor suppression via activation of VP-specific receptors in the spinal cord.",
keywords = "Analgesia, Opiates, Pain, Spinal cord, Vasopressin",
author = "Thurston, {Cindy L.} and Campbell, {Ian G.} and Culhane, {E. S.} and Earl Carstens and Watkins, {L. R.}",
year = "1992",
doi = "10.1016/0196-9781(92)90135-P",
language = "English (US)",
volume = "13",
pages = "17--25",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Characterization of intrathecal vasopressin-induced antinociception, scratching behavior, and motor suppression

AU - Thurston, Cindy L.

AU - Campbell, Ian G.

AU - Culhane, E. S.

AU - Carstens, Earl

AU - Watkins, L. R.

PY - 1992

Y1 - 1992

N2 - Intrathecal (IT) administration of vasopressin produces antinociception, scratching behavior, and motor suppression. The present experiments characterized these effects with regards to the following: 1) VP receptor specificity, 2) possible involvement of endogenous opiates, 3) possible involvement of seizure activity, and 4) whether the antinociception is due to direct actions of VP at the spinal cord. These studies showed that IT administration of a V1-specific vasopressin antagonist completely blocked the antinociception, scratching behavior, and motor suppression produced by 25 ng IT vasopressin. Furthermore, IT administration of the vasopressin metabolite, [pGlu4,Cyt6]AVP(4-9), produced none of the effects produced by vasopressin. Systemic administration of the opiate antagonists naloxone (1 mg/kg IP) and naltrexone (10 mg/kg IP) had no significant effect on the antinociception produced by IT vasopressin, whereas naltrexone potentiated the scratching behavior. Neither the IT vasopressin-induced antinociception nor scratching behavior was affected by pretreatment with the anticonvulsant sodium valproate. In addition, IT vasopressin inhibited the tail flick reflex in rats with transected spinal cords, demonstrating direct spinal effects of vasopressin. In conclusion, IT administration of vasopressin produces antinociception, scratching behavior, and motor suppression via activation of VP-specific receptors in the spinal cord.

AB - Intrathecal (IT) administration of vasopressin produces antinociception, scratching behavior, and motor suppression. The present experiments characterized these effects with regards to the following: 1) VP receptor specificity, 2) possible involvement of endogenous opiates, 3) possible involvement of seizure activity, and 4) whether the antinociception is due to direct actions of VP at the spinal cord. These studies showed that IT administration of a V1-specific vasopressin antagonist completely blocked the antinociception, scratching behavior, and motor suppression produced by 25 ng IT vasopressin. Furthermore, IT administration of the vasopressin metabolite, [pGlu4,Cyt6]AVP(4-9), produced none of the effects produced by vasopressin. Systemic administration of the opiate antagonists naloxone (1 mg/kg IP) and naltrexone (10 mg/kg IP) had no significant effect on the antinociception produced by IT vasopressin, whereas naltrexone potentiated the scratching behavior. Neither the IT vasopressin-induced antinociception nor scratching behavior was affected by pretreatment with the anticonvulsant sodium valproate. In addition, IT vasopressin inhibited the tail flick reflex in rats with transected spinal cords, demonstrating direct spinal effects of vasopressin. In conclusion, IT administration of vasopressin produces antinociception, scratching behavior, and motor suppression via activation of VP-specific receptors in the spinal cord.

KW - Analgesia

KW - Opiates

KW - Pain

KW - Spinal cord

KW - Vasopressin

UR - http://www.scopus.com/inward/record.url?scp=0026580599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026580599&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(92)90135-P

DO - 10.1016/0196-9781(92)90135-P

M3 - Article

C2 - 1535707

AN - SCOPUS:0026580599

VL - 13

SP - 17

EP - 25

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 1

ER -